Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) Financial Performance & Income Statement Overview
Explore the financials of Inhibrx Biosciences, Inc. (INBX), including yearly and quarterly data on income, cash flow, and balance sheets.
Inhibrx Biosciences, Inc. (INBX) Income Statement & Financial Overview
Analyze Inhibrx Biosciences, Inc.’s INBX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $100000.00 | $0.00 | $1.63M |
| Cost of Revenue | $0.00 | $475000.00 | $360000.00 | $298000.00 |
| Gross Profit | $0.00 | -$375000.00 | -$360000.00 | $1.34M |
| Gross Profit Ratio | $0.00 | -$3.75 | $0.00 | $0.82 |
| R&D Expenses | $38.89M | $67.63M | $63.59M | $81.84M |
| SG&A Expenses | $7.90M | $93.37M | $9.87M | $7.79M |
| Operating Expenses | $46.80M | $161.00M | $73.47M | $89.63M |
| Total Costs & Expenses | $46.80M | $161.00M | $73.83M | $89.92M |
| Interest Income | $2.89M | $2.74M | $3.30M | $4.70M |
| Interest Expense | $0.00 | $5.36M | $8.13M | $8.22M |
| Depreciation & Amortization | $760000.00 | $476000.00 | $360000.00 | $298000.00 |
| EBITDA | -$43.10M | $1.86B | -$73.47M | -$87.99M |
| EBITDA Ratio | $0.00 | $18638.00 | $0.00 | -$53.85 |
| Operating Income | -$46.80M | -$160.90M | -$73.83M | -$88.29M |
| Operating Income Ratio | $0.00 | -$1608.98 | $0.00 | -$54.03 |
| Other Income/Expenses (Net) | $2.93M | $2.02B | -$4.88M | -$3.69M |
| Income Before Tax | -$43.86M | $1.86B | -$78.71M | -$91.97M |
| Income Before Tax Ratio | $0.00 | $18580.00 | $0.00 | -$56.29 |
| Income Tax Expense | $0.00 | $2000.00 | $316724.00 | -$4000.00 |
| Net Income | -$43.86M | $1.86B | -$78.71M | -$93.60M |
| Net Income Ratio | $0.00 | $18580.00 | $0.00 | -$57.29 |
| EPS | -$2.84 | $128.35 | -$1.44 | -$1.73 |
| Diluted EPS | -$2.84 | $125.48 | -$1.44 | -$1.73 |
| Weighted Avg Shares Outstanding | $15.47M | $14.48M | $54.55M | $54.03M |
| Weighted Avg Shares Outstanding (Diluted) | $15.47M | $14.81M | $54.55M | $54.03M |
Over the last four quarters, Inhibrx Biosciences, Inc. achieved steady financial progress, growing revenue from $1.63M in Q4 2023 to $0.00 in Q3 2024. Gross profit stayed firm with margins at N/A in Q3 2024 versus 82% in Q4 2023. Operating income totaled -$46.80M in Q3 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$43.10M. Net income dropped to -$43.86M, with EPS at -$2.84. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan